CERvical Cancer The InFlammatory Index (CERTIFIKO)
CERvical Cance The InFlammatory Index as a Predictor of risK Stratification:an Observational Study
University of Campania Luigi Vanvitelli
128 participants
Nov 18, 2022
OBSERVATIONAL
Conditions
Summary
Although significant advances in screening and treatment , cervical cancer is the fifth most common female cancer in Europe. Major prognostic factors for oncological outcome are used to categorise patients at high, intermediate and low risk groups and to define the type of radical hysterectomy according "Querleu-Morrow classification". The goal of this prospective observational study is to evaluate the association between several inflammatory markers and risk groups according European guidelines in women with cervical cancer Human Papillomavirus (HPV)-associated, in order to optimize the treatment.
Eligibility
Inclusion Criteria4
- At least 18-year-old patients.
- Patients histologically diagnosed with cervical cancer (squamous cell carcinoma or adenocarcinoma HPV- associated)
- Patients with (2018 FIGO) stage ≤ IB2 ("Early Cervical Cancer")
- Patients undergoing full-body CT-scan 30 days before enrollment.
Exclusion Criteria4
- Patients unfit to plead
- Patients with chronic inflammatory diseases (IBDs; rheumatic conditions)
- Synchronous tumors or cancer diagnosis in the previous 3 years
- Patients undergoing steroid therapy in the last 30 days prior to recruitment
Interventions
Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts
histopathology findings
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05673252